Descripción

MONSTER BURNER — Monster Labs

Brand: Monster Labs
Category: High-stim thermogenic / stimulant-synergy research compound
Content: 90 capsules
Per Capsule (Label): Ephedrine 50 mg · Caffeine 250 mg · Aspirin 100 mg · 1,3-DMAA 90 mg
Price: €25
Manufactured in: Cyprus
Research Notice: For research/analytical use only. Not for human or veterinary consumption.

🧪 Product Overview

Monster Burner is a high-stimulus capsule designed around the classic
ECA (Ephedrine + Caffeine + Aspirin) framework with the addition of
1,3-DMAA, a potent indirect sympathomimetic.
Its purpose in laboratory settings is to support research on:

• thermogenesis and energy expenditure
• adrenergic pathway activation
• stimulant stacking/synergy models
• pre-exercise arousal and alertness mechanisms
• appetite and satiety perception signaling

The formula provides a clear and predictable active profile suitable for comparative analyses in metabolic, neurochemical, and stimulant-effect research workflows.

✅ Key Research Highlights

Ephedrine:
Indirect β-adrenergic agonist → ↑ norepinephrine release → lipolysis, thermogenesis, enhanced energy expenditure.
RCTs show modest short-term weight-loss effects when paired with caffeine.

Caffeine:
Adenosine A1/A2A receptor antagonist → ↑ CNS arousal, ↑ lipolysis, ↑ thermogenesis; widely studied in metabolic and performance domains.

Aspirin:
COX enzyme inhibitor; historically added to prolong adrenergic effects (evidence mixed). Included in classical “ECA” models.

DMAA (1,3-dimethylamylamine):
Potent indirect sympathomimetic → ↑ norepinephrine release; increases arousal, focus, cardiovascular activation.
Regulatory agencies classify DMAA as not lawful in U.S. dietary supplements.

🧬 Mechanism of Action (Simplified)

• Ephedrine: Increases NE release → β-adrenergic activation → thermogenesis and fat mobilization.
• Caffeine: Blocks adenosine receptors → enhances alertness and metabolic rate.
• Aspirin: Inhibits prostaglandin synthesis; historically included in ECA triads.
• DMAA: Strong CNS stimulant acting via indirect catecholamine modulation.

These combined pathways create a strong stimulant and thermogenic signal suitable for controlled laboratory comparisons with caffeine-only or ephedrine-only models.

📊 Technical Specification Table

📚 Research Background

• ECA trial: RCT (8 weeks) demonstrated increased metabolic output and moderate weight reduction compared with placebo.
• Thermogenic literature: Caffeine shown to activate brown adipose pathways and increase metabolic rate.
• Regulatory alerts: FDA prohibits ephedrine alkaloids and classifies DMAA as unlawful in supplements.

⚠️ Potential Side Effects (Class-Based Literature)

• Palpitations, tachycardia, elevated blood pressure
• Anxiety, tremor, insomnia, agitation
• Nausea, headache, GI upset
• Risk heightened when combining stimulants or exceeding serving sizes
• Serious adverse events reported in rare cases with ephedrine/DMAA

🧯 Compliance & Legal Status

Regulatory:
Ephedrine alkaloids banned in U.S. dietary supplements; DMAA not lawful in supplements.
Local restrictions apply—check your jurisdiction before acquisition or study.

Anti-Doping:
• Ephedrine prohibited in-competition >10 µg/mL urine.
• DMAA prohibited as a stimulant.
Competitive athletes must avoid exposure.

Research-only:
Product supplied exclusively for laboratory/analytical evaluation. Not for human consumption.

📌 Important Notice

For research use only. Not a medicine, not a dietary supplement, not for performance enhancement.
No human use is implied. Users are responsible for adherence to local laws, safety protocols, and anti-doping rules.